Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OK Biotech CoTPE:4155 -0.34%75 Earnings Yield (Joel Greenblatt) % is 10.89% as of Jun. 2026, which is 106% above its 10-year median of 5.28. GuruFocus rates TPE:4155 with a GF Score™ of 75/100 and a GF Value™ of NT$19.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 847 Medical Devices & Instruments companies, OK Biotech Co ranks better than 91.26% on this metric.
OK Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,782 Mil.
OK Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$303 Mil. OK Biotech Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 10.89%.
The historical rank and industry rank for OK Biotech Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TPE:4155'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -0.44 Med: 5.28 Max: 12.64
Current: 12.64
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of OK Biotech Co was 12.64%. The lowest was -0.44%. And the median was 5.28%.
TPE:4155's Earnings Yield (Joel Greenblatt) % is ranked better than 91.26% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 1.13
vs TPE:4155: 12.64
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. OK Biotech Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was -9.19%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
OK Biotech Co (TPE:4155) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
OK Biotech Co Earnings Yield (Joel Greenblatt) % Related Terms
OK Biotech Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, OK Biotech Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's Earnings Yield (Joel Greenblatt) % falls into.
OK Biotech Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
OK Biotech Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
OK Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$303 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 10.89% mean?
OK Biotech Co (TPE:4155) has a Earnings Yield (Joel Greenblatt) % of 10.89% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on OK Biotech Co and its competitors. This is 106% above median its historical median of 5.28. According to the industry distribution chart, OK Biotech Co ranks #74 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is OK Biotech Co's Earnings Yield (Joel Greenblatt) % too high?
OK Biotech Co's current Earnings Yield (Joel Greenblatt) % of 10.89% is 106% above median its 10-year median of 5.28. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 1.13. OK Biotech Co's value of 10.89% is 863.7% above this industry median. Based on the distribution chart, OK Biotech Co ranks #74 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OK Biotech Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #74 out of 847 companies for Earnings Yield (Joel Greenblatt) %. This places OK Biotech Co in the top 9% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 1.13. OK Biotech Co's value of 10.89% is 863.7% above this benchmark. While the company's 10-year median is 5.28 vs. the industry median of 1.13, OK Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 1.13, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current Earnings Yield (Joel Greenblatt) % of 10.89% is 863.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current Earnings Yield (Joel Greenblatt) % is 10.89%, which is 106% above median its own 10-year median of 5.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$19.89, compared to a current price of NT$14.45 — trading 27.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 10.89%, which is 106% above median its 10-year median of 5.28 and 863.7% above the Medical Devices & Instruments industry median of 1.13. OK Biotech Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current Earnings Yield (Joel Greenblatt) % is 10.89% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$14.45 is trading 27.4% below its estimated GF Value™ of NT$19.89.
GuruFocus considers OK Biotech Co to be Modestly Undervalued.
Key valuation signals for TPE:4155:
Earnings Yield (Joel Greenblatt) %: 10.89% (106% above median its 10-year median of 5.28)
GF Value™: NT$19.89 vs. price of NT$14.45 (27.4% below fair value)
Industry Position: 863.7% above the Medical Devices & Instruments median (#74 of 847)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
75GF Score
Get the complete analysis for TPE:4155
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
